A single armed and open labelled trial in patients with hepatocellular carcinoma and HBV infection (HBsAg+) post liver transplantation. For patients who successfully match TCR histocompatibility locus antigen (HLA) restriction, escalating doses of HBV/TCR expressing autologous T cells will be infused. Tests will be done to confirmed safety and efficacy during the two-month treatment and observation period and twice each year of a follow up period up to five years.